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Abstract
Background: The clinical problem of a ‘‘pure volume overload’’ as in isolated mitral or aortic regurgitation currently has no
documented medical therapy that attenuates collagen loss and the resultant left ventricular (LV) dilatation and failure. Here,
we identify a potential mechanism related to upregulation of the kallikrein-kinin system in the volume overload of
aortocaval fistula (ACF) in the rat.
Methodology/Principal Findings: LV interstitial fluid (ISF) collection, hemodynamics, and echocardiography were
performed in age-matched shams and 4 and 15 wk ACF rats. ACF rats had LV dilatation and a 2-fold increase in LV end-
diastolic pressure, along with increases in LV ISF bradykinin, myocardial kallikrein and bradykinin type-2 receptor (BK2R)
mRNA expression. Mast cell numbers were increased and interstitial collagen was decreased at 4 and 15 wk ACF, despite
increases in LV ACE and chymase activities. Treatment with the kallikrein inhibitor aprotinin preserved interstitial collagen,
prevented the increase in mast cells, and improved LV systolic function at 4 wk ACF. To establish a cause and effect
between ISF bradykinin and mast cell-mediated collagen loss, direct LV interstitial bradykinin infusion in vivo for 24 hrs
produced a 2-fold increase in mast cell numbers and a 30% decrease in interstitial collagen, which were prevented by BK2R
antagonist. To further connect myocardial stretch with cellular kallikrein-kinin system upregulation, 24 hrs cyclic stretch of
adult cardiomyocytes and fibroblasts produced increased kallikrein, BK2R mRNA expressions, bradykinin protein and
gelatinase activity, which were all decreased by the kallikrein inhibitor-aprotinin.
Conclusions/Significance: A pure volume overload is associated with upregulation of the kallikrein-kinin system and ISF
bradykinin, which mediates mast cell infiltration, extracellular matrix loss, and LV dysfunction–all of which are improved by
kallikrein inhibition. The current investigation provides important new insights into future potential medical therapies for
the volume overload of aortic and mitral regurgitation.
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Introduction
There is currently no medical therapy that attenuates the
eccentric left ventricular (LV) remodeling in the clinical pure
volume overload of mitral or aortic regurgitation [1–3]. It is of
interest that, as opposed to LV pressure overload, LV volume
overload is associated with a decrease in interstitial collagen
surrounding cardiomyocytes [4–6]. The pure volume overload of
aortocaval fistula (ACF) in the rat causes a LV stretch stimulus
without an increase in LV pressure due to the arterial-venous
shunt. As in the human with a pure volume overload, over time
this results in an adverse LV eccentric remodeling manifested by
increases in LV end-diastolic pressure and LV end-diastolic
dimension to wall thickness ratio. We have shown that LV
dilatation and collagen degradation occur even before cardiomy-
ocyte elongation [4] supporting the hypothesis that interstitial
collagen loss and/or disruption is central to adverse LV
remodeling in the volume overload of ACF. We have also shown
that the highly tissue specific angiotensin I-converting enzyme
(ACE) inhibitor ramipril further exacerbates the loss of collagen
and LV eccentric remodeling without improving LV shortening
despite decreasing mean arterial pressure [4]. Thus, the anti-
fibrotic and antihypertrophic effects of a pure volume overload are
a poor match for renin-angiotensin system blockade and may thus
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e40110explain why such therapy does not attenuate LV remodeling in
patients with isolated MR [2,3]. Taken together, it is tempting to
speculate that ACE inhibition, which decreases angiotensin II and
increases bradykinin, exacerbates collagen loss and thus fails to
prevent LV dilatation in a pure volume overload.
The potential pathophysioloic role of bradykinin in an isolated
volume overload is of particular interest because we have
previously demonstrated an increase in interstitial fluid (ISF) of
bradykinin [5] and significant attenuation of LV dilatation with
bradykinin type 2 receptor (BK2) in the early phase of ACF in the
rat [4,5]. In addition to decreasing collagen I and III mRNA
production in cardiac fibroblasts [7], bradykinin also modulates
matrix metalloproteinase (MMP) activation through the plasmin-
ogen activator system [8] and increases MMP-2 and MMP-9
expression [9,10]. Thus, in the opposite hemodynamic stimulus of
pressure overload, kallikrein gene delivery attenuates LV hyper-
trophy and fibrosis in the spontaneously hypertensive rat [11] and
in rats with aortic banding [12]. In addition, direct bradykinin
delivery attenuates fibrosis in an experimental model of liver
fibrosis [13].
Bradykinin also stimulates proinflammatory cytokine produc-
tion by mast cells and is chemotactic for polymorphonuclear cells
[14,15]. Mast cells are increased in the acute and chronic phase of
ACF [5,6] and are decreased by treatment with BK2 receptor
blockade in five day ACF rats [5]. Mast cell degranulation causes
the release of proteolytic enzymes like tryptase and chymase, as
well as other cytokines that activate MMPs [16]. We have also
demonstrated that mast cells possess BK2 receptors and that direct
bradykinin interstitial infusion causes mast cell degranulation and
chymase release into the interstitial fluid space in wild type mice
in vivo [17]. In addition to Ang II-forming capacity, chymase also
can activate kallikrein which further increases tissue bradykinin
[18].
The purpose of the current study is to understand the
mechanisms of extracellular matrix loss in volume overload with
the aim of identifying potential new targets that prevent
progressive LV remodeling and failure. Through a series of in
vivo and in vitro experiments, we demonstrate that chronic
myocardial stretch of a pure volume overload causes upregulation
of the kallikrein-kinin system. We present further evidence that the
resulting increase in ISF bradykinin in volume overload can
mediate mast cell infiltration and extracellular matrix loss that are
prevented by kallikrein blockade in vivo and result in improved LV
function.
Results
Morphologic, Hemodynamic and Echocardiographic
Data
Total heart weight, LV and RV weight to body weight ratio and
lung weight were increased significantly in both 4 and 15 wk ACF
vs. age-matched sham rats (Table 1). Mean arterial pressure was
decreased .15% at 4 and 15 wk ACF, while LV end-diastolic
(ED) pressure and wall stress increased significantly at 4 wk and
15 wk ACF rats (Table 2). However, LV end-systolic (ES) wall
stress did not differ from aged-matched shams at 4 and 15 wk
ACF due to a decreased in mean arterial pressure that offset the
significant increase in LVES dimension. LV +dP/dtmax did not
differ from age-matched shams at both time points, while LV -dP/
dtmax at 15 wk ACF was decreased below 15 wk sham rats. LVED
dimension (LVEDD), LVED wall stress, and LVEDD/posterior
wall thickness ratio were increased at 4 and 15 wk ACF rats
(Table 2), consistent with adverse LV remodeling. At 15 wk there
was a significant decrease in LV fractional shortening, while at
4 wk ACF LV fractional shortening did not differ from age-
matched shams. Although our results showed age-related changes
between 4 and 15 wk shams, Bolyut et al. has reported that older
rats may have a greater cardiovascular susceptibility to isoflurane
anesthesia [19]. Nevertheless, directional changes in hemodynam-
ics from sham to ACF at both 4 and 15 wks are the same. Our
goal in this study was to investigate time-related responses to ACF
volume overload by using age-matched shams.
Interstitial (ISF) and Plasma Bradykinin, Ang II,
Catecholamine
ISF bradykinin levels were increased at 4 and 15 wk ACF vs.
age-matched sham rats (Table 3), while ISF Ang II was increased
only at 4 wk ACF rats. At 15 wk ACF, ISF Ang II did not differ
from age-matched shams, while ISF bradykinin was increased
40% compared to age-matched shams (Table 3). Thus, ISF
bradykinin either offset increased ISF Ang II at 4 wk ACF or was
increased above ISF Ang II at 15 wk ACF compared to age-
matched shams. However, plasma Ang II and bradykinin levels
were both increased at 4 and 15 wk ACF rats in response to
volume overload. ISF and plasma norepinephrine (NE) and
epinephrine (E) did not differ from age-matched shams at 4 wk
ACF but were both significantly increased at 15 wk ACF.
LV ACE, ACE 2, Chymase Activity and Mast Cell Numbers
LV ACE activity was increased at 15 wk ACF vs. age-matched
sham rats. LV chymase activity and mast cell density increased
throughout the course of volume overload (Figure 1, n=8–10 in
each group). Western blots analyses demonstrated unchanged of
ACE 2 protein in LV homogenates in age-matched shams
(1.0860.06) and 4 wk ACF rats. However, ACE 2 protein
expression was markedly increased at 15 wk ACF rats
(1.4960.12, Figure S1, n=6). Further, LV ACE 2 activity was
increased two-fold at 15 wk ACF vs. age-matched sham rats
(11.1560.30 vs. 5.0560.52 fmol/min/mg protein, n=6).
Kallikrein (KLK) 1, 2, 10, BK2R and ACE 2 Expressions in
ACF
Kallikrein 1, 2, 10 and BK2 receptor mRNA expressions were
increased throughout ACF. ACE 2 expression was unchanged at
4 wk ACF rats but increased 50% at 15 wk ACF vs. age-matched
sham rats (Figure 2, n=6–8 in each group).
Table 1. Morphologic data at 4 and 15 wk rats.
4 wk Sham 4 wk ACF
15 wk
Sham
15 wk
ACF
(n=8) (n=8) (n=10) (n=10)
HW (g) 0.9860.05 1.5560.06* 1.2660.03
{ 2.2360.11*
BW (g) 359620 35469 471610
{ 489615
HW/BW (g/kg) 2.760.1 4.460.2* 2.760.1 4.860.3*
LVW/BW (g/kg) 2.160.1 3.160.1* 1.960.1 3.160.1*
RVW/BW (g/kg) 0.560.1 0.960.1* 0.560.1 1.060.1*
Lung wt (g) 1.4660.09 1.8460.08* 1.9760.06
{ 2.4460.11*
Values are expressed as mean6SEM. In each group, values in parentheses
represent n.* P,0.05 vs. age-matched shams.
{P,0.05 vs. 4 wk shams. ACF:
aortocaval fistula; HW: heart weight; BW: body weight; LVW: left ventricle
weight; RVW: right ventricle weight.
doi:10.1371/journal.pone.0040110.t001
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Myocardium
Tissue kallikrein protein expressions were demonstrated in
cardiomyocytes and interstitium of the volume overloaded heart
(Figure 3). There were increased tissue kallikrein proteins at 4 and
15 wk ACF vs. age-matched sham rats (Figure 3B–E).
Interstitial Collagen Volume Percent Analysis in ACF
Interstitial collagen volume percent by staining with picric acid
Sirius red F3BA (PASR) was decreased 30% at 4 and 15 wk ACF
vs. age-matched shams (Figure 4, n=8–10 in each group).
In vivo Effect of Bradykinin on LV Mast Cell Infiltration,
Degranulation and Interstitial Collagen Loss
To establish a direct link between ISF bradykinin and
extracellular matrix loss, we infused bradykinin (5 ng/ml) into
the interstitial space through a microdialysis catheter placed in the
LV myocardium of normal rat for 24 hrs with and without BK2R
antagonist (Hoe-140, 0.5 mg/kg/d given by osmotic infusion
pump). Interstitial bradykinin infusion increased LV mast cells
two-fold compared to interstitial saline infusion in vehicle control
rats, which was prevented by Hoe-140 treatment (Figure 5F,
n=6). In a similar fashion, interstitial collagen volume percent by
PASR was decreased 30% in the interstitial bradykinin infusion
group and prevented by Hoe-140 compared to vehicle controls
(Figure 5A–C and E, n=6).
Effect of Aprotinin on Collagen Volume %, Mast Cells,
Hemodynamics and LV Remodeling at 2 Day and 4 Wk
ACF
Aprotinin (12,000 kallikrein inhibitor units, twice daily, sc), a
serine protease inhibitor capable of inactivating kallikreins,
prevented the decrease in LV interstitial collagen volume percent
after 2 day and 4 wk of ACF without an increase in heart rate or
mean arterial pressure (Figure 6A–E, n=7–8, Table 4). LV mast
cells were increased .30% at 4 wk ACF compared to age-
matched sham rats which were prevented by aprotinin (Figure 6F,
n=7–8). At 2 day ACF, body weight or heart weight/body weight
ratio did not differ among sham, ACF, sham+aprotinin and
ACF+aprotinin rats (data not shown). Treatment did not attenuate
the two-fold increase in LVEDP and had no effect on the increase
in LV fractional shortening with ACF. However, at 4 wk post-
ACF rats, aprotinin decreased LVES dimension and a trend
toward decreased LVES wall stress. This was accompanied by an
increase improvement in LV fractional shortening, ejection
fraction and a trend of increase velocity of circumferential fiber
shortening compared to untreated 4 wk ACF rats.
In vitro Effect of Cell Stretch on Kallikrein Kinin and
Gelatinase Expression
Primary cultured adult cardiac myocytes and fibroblasts
underwent cyclic mechanical stretch to simulate volume overload.
Cyclic stretch of these cells produced a .two-fold increase
kallikrein 1, 10 and BK2R mRNA expressions in cell lysate and
prevented by aprotinin (Figure S2, n=4–5 in each group). In
cardiomyocytes, bradykinin level increased 6-fold in the culture
media (1.26 vs. 7.83 ng/ml, un-stretched vs. 24 hrs stretched,
P,0.01, n=6). In the fibroblast culture media, bradykinin levels
increased from undetectable value (un-stretched) to 1.64 ng/ml
Table 2. Hemodynamic and echocardiographic data at 4 and
15 wk rats.
4w k
Sham 4 wk ACF
15 wk
Sham
15 wk
ACF
(n=8) (n=8) (n=10) (n=10)
HR (beats/min) 260612 271611 217612
{ 22065
MAP (mmHg) 114649 5 63* 9564
{{ 8264*
LVEDP (mmHg) 2617 61* 5619 61*
LV+dP/dt
(mmHg/sec)
80316440 89476745 75296445 66006289
LV-dP/dt
(mmHg/sec)
274796337 269956458 254016358
{242446222*
LVEDD (mm) 7.060.2 10.160.3* 9.060.1
{ 11.660.4*
LVESD (mm) 4.360.3 6.360.3* 5.660.1
{ 7.460.3*
LVEDD/PW 4.860.3 7.760.5* 5.960.3 7.960.4*
LVED-WS (g/cm
2) 3611 4 63** 761
{ 1661*
LVES-WS (g/cm
2) 67613 77687 2 678 0 66
LVFS (%) 38643 8 624 0 613 4 62*
Values are expressed as mean6SEM. In each group, values in parentheses
represent n.* P,0.05, **P,0.01 vs. age-matched shams.
{P,0.05,
{{P,0.01 vs.
4 wk shams. ACF: aortocaval fistula; HR: heart rate; MAP: mean arterial pressure;
LVEDP: LV end-diastolic pressure; LV+dP/dt: LV pressure derivative maximum;
LV-dP/dt: LV pressure derivative minimum. LVEDD: LV end-diastolic dimension;
LVESD: LV end-systolic dimension; LVEDD/PW: LV end-diastolic dimension to
posterior wall thickness ratio; LVED-WS: LV end-diastolic wall stress; LVES-WS: LV
end-systolic wall stress; LV FS: LV fractional shortening.
doi:10.1371/journal.pone.0040110.t002
Table 3. Interstitial and plasma Ang II, bradykinin and catecholamine at 4 and 15 wk rats.
ISF Plasma
Ang II
(pg/hr)
BK
(pg/hr)
NE
(pg/hr)
E
(pg/hr)
Ang II
(pg/ml)
BK
(pg/ml)
NE
(pg/ml)
E
(pg/ml)
4 wk Sham (8) 1.560.2 6.460.4 6.261.0 3.560.3 29631 0 619 3 612 83612
4 wk ACF (9) 3.060.4* 9.361.1* 6.860.8 5.360.9 10767** 2862** 89689 1 621
15 wk Sham (8) 1.660.2 7.461.4 5.960.4 3.560.4 34641 7 621 0 2 616 7566
15 wk ACF (10) 1.960.1 12.461.7* 10.261.0* 8.661.1** 65613* 2965* 159617* 101611*
Values are expressed as mean6SEM. In each group, values in parentheses represent n.* P,0.05, **P,0.01 vs. age-matched shams. ISF: interstitial fluid; ACF: aortocaval
fistula; Ang II: angiotensin II; BK: bradykinin; NE: norepinephrine; E: epinephrine.
doi:10.1371/journal.pone.0040110.t003
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myocytes and fibroblasts produced a little increase in MMP-9 and
two-fold increases in MMP-2 activity (Figure S3, n=4–5),
respectively. Western blots showed undetectable MMP-9 expres-
sion but a .30% increase MMP-2 expression in both stretched
cells and inhibited by aprotinin (Figure S3, n=4–5).
Discussion
In the current investigation, we show how the increase in the
LV kallikrein-kinin system expression can explain interstitial
collagen loss and inflammatory cell infiltration that have been
central to the pathophysiology of LV dilatation in a chronic pure
volume overload. Rat cardiomyocytes produce mRNA for
kininogen, kallikrein, and kinin receptors [20] and the rat heart
contains a kininogen-like protein that is elevated with acute
inflammation [21] and chronic volume overload [22]. To connect
kallikrein-kinin system upregulation with the myocardial stretch of
volume overload, the current study demonstrates that 24 hrs cyclic
stretch of adult cardiac myocytes and fibroblasts results in
increased cellular kallikreins and BK2R mRNA expression and
increased bradykinin release. Further, kallikrein protein is
demonstrated in cardiomyocytes and LV ISF bradykinin is
increased in ACF in vivo, supporting cardiomyocyte and fibroblast
bradykinin production with volume overload.
The loss of collagen and increased kallikrein-kinin system
expression with ACF contrasts with an increase in collagen
synthesis and down regulation of LV BK2 receptor mRNA in the
pressure overloaded rat heart [23]. Thus, it is tempting to
speculate that upregulation of the LV kallikrein-kinin system in
volume overload produces an anti-fibrotic phenotype that
promotes a more compliant LV chamber. However, the delete-
rious effects of prolonged kallikrein-kinin system expression and
collagen loss in volume overload pose a unique therapeutic
problem, because treatment with conventional renin-angiotensin
system blockade decreases rather than promotes collagen produc-
tion. In the current study, kallikrein inhibitor-aprotinin prevents
loss of interstitial collagen in 2 day and 4 wk of ACF without an
increase in mean arterial pressure. Aprotinin also decreases LVES
dimension and increases in fractional shortening and ejection
fraction, along with trends toward increased velocity of circum-
ferential shortening and +dP/dtmax and –dP/dtmax. We speculate
that improvement in these load dependent indices of LV function
results from a more efficient transmission of forces between
adjacent myofibers and myocytes due to preservation of interstitial
collagen.
We postulate that the acute (2 day) and subacute (4 wk) volume
overload causes upregulation of kallikrein and bradykinin resulting
in a negative extracellular matrix homeostatic balance in which
MMP activation dominates over collagen synthesis. Dolgilevich
et al. demonstrate a decrease in collagen mRNA at 45 days and an
increase in collagenase mRNA expression at 14 days of ACF [24].
Further, MMP-2 activity is increased in both acute and chronic
ACF [6,25]. Stretch of cardiac fibroblasts in vitro has also been
shown to increase collagenase activity and membrane type-
1 MMP expression [26]. We also show that cyclic stretch of adult
cardiomyocytes and fibroblasts produces a 20% increase in MMP-
9 and two-fold increase MMP-2 gelatinase activity and kallikrein 1
gene expression that are decreased by aprotinin (Figures S2 and
S3). These results in vitro support the beneficial effect of aprotinin
in preserving interstitial collagen and improving LV function in
the 2 and 4 wk ACF.
Another important component to the pathophysiology of LV
remodeling in a pure volume overload is inflammatory cell
Figure 1. Increasing LV ACE and chymase activity and mast cell
numbers in ACF. (A) By using ACE-specific substrate hippuryl-his-leu,
LV myocardium ACE activity was defined as captopril-inhibitable
hippuric acid (HA) formation expressed as nmoles of HA formed/g/
min of tissue. (B) By using Ang I as substrate, chymase-like activity was
defined as chymostatin-inhibitable Ang II formation expressed as
nmoles of Ang II formed/min/g of tissue. Both activities were measured
at 4 and 15 wk age-matched shams and ACF rats. (C) The number of
mast cells was quantitatively determined for the entire LV wall using
Giemsa-stained paraffin sections. LV mast cell numbers were increased
at the 4 and 15 wk ACF rats vs. age-matched shams. Values are
mean6SEM. n=8–10 in each group. *P,0.05, **P,0.01 vs. age-
matched shams.
doi:10.1371/journal.pone.0040110.g001
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isolated mitral regurgitation [28] and in the rat with ACF [5,6].
Bradykinin is a well known chemotactic stimulus for many types of
inflammatory cells [29]. We have demonstrated BK2 receptors on
mast cells and that BK2 receptor blockade prevents ACE inhibitor-
mediated increases in LV ISF chymase activity in the normal
mouse [17] and mast cell accumulation in the 5 day ACF rat [5].
To connect ISF bradykinin with mast cell and collagen loss, the
current study demonstrates that cardiac interstitial bradykinin
infusion increases mast cell numbers and causes collagen loss, both
of which are prevented by BK2 receptor blockade. Furthermore,
kallikrein inhibitor-aprotinin prevents the increase of mast cell
numbers and loss of interstitial collagen in 4 wk ACF.
It is important to note that in the 15 week ACF there are patchy
areas of LV endocardial perivascular fibrosis, despite the loss of
collagen surrounding cardiomyocytes. A similar finding has been
reported in the failing human heart where perivascular fibrosis
occurs in combination with loss of cardiomyocyte interstitial
collagen [30]. Taken together, these findings suggest a compart-
mentalization of collagen homeostasis in the failing heart, with
collagen loss surrounding cardiomyocytes and a perivascular
fibrosis. However, it is of interest that in the aortas of 30 month old
rats, MMP pro-inflammatory effects result in an increase in
collagen formation and vascular stiffening [31]. It is important to
note that in the current investigation, ACF is induced at 10 week
old rats and continues for 15 weeks–raising the question whether a
more diffuse pattern of fibrosis may occur in older rats.
The current study also reports discordant ISF and plasma
Ang II levels. In the rat, the largely interstitial enzyme chymase
has multiple isoforms, in particular b-chymase, which can
Figure 2. Increasing expressions of kallikreins (KLKs), BK2 receptor and ACE 2 mRNA in ACF. Total RNA was extracted from LV tissue with
TRIzol reagent. Expressions of kallikrein 1, 2, 10 and BK2 receptor and ACE 2 mRNA in normalized to GAPDH at 4 and 15 wk ACF rats compared to
age-matched shams. Values are mean6SEM. n=6–8 in each group. *P,0.05, **P,0.01 and ***P,0.001 vs. age-matched shams.
doi:10.1371/journal.pone.0040110.g002
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the formalin fixed paraffin-embedded LV. Image acquisition (100x objective, 4000x video-screen magnification) was performed on a Leica DM6000
epifluorescence microscope with SimplePCI software. LV tissues were stained with anti-tissue kallikrein (red), anti-desmin (green), and DAPI (blue).
Representative images of the sections: (A) negative control (cross section), (B) 4 wk sham (cross section), (C) 4 wk ACF (cross section), (D) 15 wk sham
(longitudinal section), (E) 15 wk ACF (longitudinal section). Arrows demonstrate tissue kallikrein in the LV myocytes or interstitium of each group. Bar
scale: 10 mm.
doi:10.1371/journal.pone.0040110.g003
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e40110Figure 4. Determination of interstitial collagen volume percent in sham and ACF rats. Representative images of LV interstitial collagen
stainedwithpicricacidsiriusredF3BA(PASR)weremeasuredat4and15 wkACFandtheirage-matchedshamrats.Thelossofinterstitialcollagen(shown
as dark collagen fibers excluding perivascular areas) between cardiomyocytes at 4 and 15 wk ACF was reflected by the decrease in collagen volume
percent(%). Howeverfrominsets,whencomparingthe4 and15 wk ACF,thereis anobviousincreasein perivascularcollagencomparedtoshamin the
15 wk ACF. Panel in the bottom displays quantification of the interstitial collagen at 4 and 15 wk ACF and their age-matched shams. Values are
mean6SEM. n=8–10 in each group. *P,0.05 vs. age-matched shams. Bar scale: 20 mm and 40 mm in insets.
doi:10.1371/journal.pone.0040110.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e40110Figure 5. Effect of LV interstitial bradykinin infusion on mast cell infiltration, degranulation and collagen loss. Interstitial collagen
volume percent was decreased 30% by bradykinin infusion group (B) compared to saline infused vehicle control (A) and prevented by Hoe-140
(C). Infusion of bradykinin into LV myocardium increased mast cell number by 2-fold compared to vehicle group and mast cell increases were
inhibited by Hoe-140 (F). Representative image (D) demonstrates mast cells and mast cell granules show degranulation after interstitial bradykinin
infusion. The number of mast cell was quantitatively determined for the entire LV wall using Giemsa-stained paraffin sections. It produces intense
staining (purple) specific for mast cell granules. Panel (E) displays quantification of the interstitial collagen of normal rat with interstitial saline or
bradykinin (5 ng/ml) infusion for 24 hrs with and without BK2R antagonist (Hoe-140, 0.5 mg/kg/d given by osmotic infusion pump). Values are
mean6SEM. n=6 in each group. ***P,0.001 vs. Vehicle.
{P,0.05 vs. bradykinin infusion plus Hoe 140. **P,0.01 vs. Vehicle and bradykinin
infusion plus Hoe-140. Bar scale: 20 /m.
doi:10.1371/journal.pone.0040110.g005
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protein are increased along with a two-fold increase in ACE2
activity in the LV of 15 wk ACF (Figure S1). ACE 2 is a
carboxypeptidase that converts Ang I and Ang II to Ang-(1–7)
[33,34]. Ang-(1–7) exerts counter-regulatory effects of Ang II
through a specific pathway involving a novel Ang-(1–7) receptor
and is an endogenous inhibitor of the C-terminal active site of
ACE [33]. More importantly, ACE 2 has a catalytic activity for
Ang II that is 400 fold higher than for Ang I. Taken together,
the decrease ISF Ang II in the 15 wk ACF may be due to an
Figure 6. Effect of aprotinin on interstitial collagen volume percent and mast cells in 4 wk ACF. Interstitial collagen volume percent was
decreased .30% at 4 wk ACF (B) compared to age-matched sham rats (A) and prevented by aprotinin (D). Panel (C) represents sham with aprotinin
treatment which displays no change in the interstitial collagen volume % compared to Vehicle treated sham. Quantification of the interstitial collagen
volume % and mast cells were shown in Panels E and F. Mast cell numbers were increased in the 4 wk ACF rats and decreased by aprotinin (F). Values
are mean6SEM. n=7–8 in each group. *P,0.05 vs. Vehicle treated age-matched shams.
{P,0.05 vs. Vehicle treated ACF rats.
doi:10.1371/journal.pone.0040110.g006
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decrease ISF Ang II and increase ISF Ang-(1–7), which in
combination with the increase in ISF BK decrease interstitial
collagen production in the 15 wk ACF.
The in vivo and in vitro results of the current investigation
summarized in Figure 7 demonstrate that a pure volume
overload/stretch is associated with upregulation of the kallikrein-
kinin system and increased ISF bradykinin, which mediates
mast cell infiltration, extracellular matrix loss, and LV
dysfunction–all of which are improved by kallikrein inhibition-
aprotinin. However, at 15 wk ACF stage, there is an increase in
LV ISF catecholamines, perivascular fibrosis, and a decrease in
LV function, which at that time point forward may benefit from
full rennin-angiotensin system blockade. However, in the early
phase, ACE inhibition may in fact exacerbate the process by
causing a further increase in ISF bradykinin, a decrease
extracellular matrix synthesis, and mast cell recruitment and
degranulation. This study demonstrates that LV remodeling is
truly a diverse process that is dependent upon the type and
stage of the cardiac stress, as well as the age of the patient. In
the particular case of a pure volume overload, studies are
ongoing to uncover novel drug targets that control inflammation
and collagen loss in the early stages and thus attenuate LV
remodeling and prolong the time to development of heart
failure.
Methods
Ethics Statement
These studies conform to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85–23, revised 1996), and was
approved by the University of Alabama at Birmingham’s
Institutional Animal Care and Use Committee (Approved protocol
#111009251). The protocol for purification of tissue kallikrein
antibody was approved by the Institutional Animal Care and Use
Committee at the Medical University of South Carolina.
Creation of Aortocaval Fistula (ACF) in the Rat
ACF or sham surgery was performed on 10-week old male
Sprague-Dawley rats (200–250 g) under sterile conditions using
isoflurane anesthesia as previously described in our laboratory
[4,5]. Briefly, a ventral abdominal laparotomy was performed to
expose the aorta and caudal vena cava ,1.5 cm below the renal
arteries. Blunt dissection removed the overlying adventitia and
exposed the vessels, taking care not to disrupt the tissue
connecting the vessels. Both vessels were then occluded proximal
and distal to the intended puncture site, and an 18-guage needle
was inserted into the exposed abdominal aorta and advanced
through the medial wall into the vena cava to create the fistula.
The needle was withdrawn and the ventral aortic puncture was
sealed with cyanoacrylate. Creation of the ACF was visualized by
the pulsatile flow of oxygenated blood into the vena cava. The
abdominal musculature and skin incisions were closed by
standard techniques with absorbable suture and autoclips. The
control animals, sham, underwent general anesthesia and an
abdominal incision without ACF.
Cardiac Microdialysis in vivo and Interstitial Fluid
Collection
Cardiac microdialysis probes were inserted into the LV
myocardium in 4 and 15 wk ACF and in age-matched sham rats.
Interstitial fluid collections were performed in the conscious state
as previously described in our laboratory [5]. Each microdialysis
probe had a semipermeable membrane fiber (AN69, Hospal,
Table 4. Effect of aprotinin on hemodynamics and LV remodeling at 2 day and 4 wk rats.
2 day 4 wk
Sham
(n=5)
ACF
(n=5)
Sham+Apr
(n=5)
ACF+Apr
(n=5)
Sham
(n=7)
ACF
(n=8)
Sham+Apr
(n=7)
ACF+Apr
(n=8)
HR (beats/min) 35966 367683 7 1 643 7 5 612 321673 0 7 633 1 2 653 1 6 63
MAP (mmHg) 100628 9 631 0 6 618 4 65* 107639 0 62* 106658 6 62*
LVEDP (mmHg) 6611 1 615 611 1 62* 4601 0 61* 4611 0 61*
LVESP (mmHg) 55636 1 635 8 625 7 648 5 637 5 628 6 657 0 63*
LV+dP/dt (mmHg/s) 87676391 93866260 83016442 90656354 85056450 81166348 79316415 89376423
LV-dP/dt (mmHg/s) 274746152 287976411 284746123 278796530 273796445 259486131* 274226236 268346333
LVEDD (mm) 6.960.2 8.260.2* 7.060.1 8.060.1* 7.760.2 10.660.3* 7.660.1 10.260.2*
LVESD (mm) 4.060.2 4.360.5 4.160.2 4.060.2 4.760.2 6.860.3* 4.760.2 5.960.2*
{
LVEDD/PW 4.660.2 5.860.2* 4.660.3 5.460.4 4.260.2 5.760.3* 4.560.4 6.060.4*
LV FS (%) 41624 8 654 3 625 0 633 8 623 7 613 9 614 3 61
{
LV EF (%) 66637 6 657 2 627 9 636 6 626 3 626 7 627 1 61
{
VCFr (%) 8.360.6 10.260.5 9.860.8 10.160.6 7.960.8 5.760.2 7.560.5 7.460.6
LVED-WS (g/cm
2) 4611 6 61* 6611 6 64* 4611 5 62* 4611 6 62*
LVES-WS (g/cm
2) 50635 4 634 9 693 7 676 5 658 1 686 8 686 2 66
Coll Vol (%) 3.960.2 2.160.1* 4.060.3 3.660.2
{ 3.560.1 2.460.1* 3.560.1 3.260.1
{
Values are expressed as mean6SEM. In each group, values in parentheses represent n.* P,0.05 vs. age-matched shams.
{P,0.05 vs. ACF. ACF: aortocaval fistula; Apr:
aprotinin; HR: heart rate; MAP: mean arterial pressure; LVEDP: LV end-diastolic pressure; LV+dP/dt: LV pressure derivative maximum; LV-dP/dt: LV pressure derivative
minimum. LVEDD: LV end-diastolic dimension; LVESD: LV end-systolic dimension; LVEDD/PW: LV end-diastolic dimension to posterior wall thickness ratio; FS: fractional
shortening; EF: ejection fraction; VCFr: velocity of circumferential fiber shortening; LVED-WS: LV end-diastolic wall stress; LVES-WS: LV end-systolic wall stress; Coll Vol
(%): interstitial collagen volume percent.
doi:10.1371/journal.pone.0040110.t004
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diameter <250 mm) with Pebax tubing (outer diameter <200 mm)
inserted and sealed in each end of the fiber such that ,4m mo f
fiber remained exposed at the center of the assembly; this exposed
region resided within the LV myocardium free wall. After
implantation, the probe was perfused with 0.9% saline using a
precision infusion syringe pump (BAS, IN) at a flow rate of 1.0 ml/
min. The dialysate was collected from the outflow tubing in
eppendorf tubes on ice with 5 ml of EGTA with reduced
glutathione for catecholamine, 10 ml acetic acid (1.0 M) for Ang
II peptides, and 98% ethanol for BK and frozen at 280uC until
biochemical analysis. Two 10-hr dialysate were collected for ISF
bradykinin and Ang II and two 4-hr dialysate were collected for
norepinephrine (NE) and epinephrine (E) analysis over a total
28 hr period beginning 24 hrs after surgery recovery from dialysis
probe implantation. At the end of the interstitial collection, Evans
blue was introduced into the probe to visually check if the probe
was positioned correctly in the LV.
Osmotic Pump Infusion of BK
We infused BK (5 ng/ml) into the interstitial space through a
microdialysis catheter placed in the LV myocardium of normal rat
for 24 hours with and without BK2R antagonist (Hoe-140,
0.5 mg/kg/day, American Peptide Company, Sunnyvale, CA)
and was given by osmotic infusion pump subcutaneous (model
2001, 7 days, Alzet, Cupertino, CA,).
Hemodynamic and Echocardiographic Measurement
Because of the potential effects of the probes and infusions on
tissue, we did not use above microdialysis rats for tissue analysis. A
subset of animals was used for hemodynamic and echocardio-
graphic measurement. At the time of sacrifice aortic pressure, LV
peak systolic and LV end-diastolic pressure, peak +/2 dP/dt were
measured in anesthetized animals with an intravascular pressure
transducer (model SPR-249A Millar Mikro-Tip catheter trans-
ducer, Millar Instruments, Houston, TX) introduced via the right
carotid artery into the LV chamber. High-fidelity LV pressure was
recorded concurrent with echocardiography (Agilent Sonos 5500,
Philips, Bothel, WA). LV wall stress and function were calculated
as previously described [4]. Venous blood was collected for BK
and Ang II measurement under isoflurane anesthesia by venous
puncture of the abdominal inferior vena cava. After sacrifice,
whole heart, LV, RV and lungs were weighed. LV tissue was
collected for evaluation of kallikreins, BK2 receptor and ACE 2
expressions, chymase activity, mast cell numbers and interstitial
collagen volume percent.
Ang II, BK and Catecholamine Concentration
Plasma Ang II concentration was determined by a method
described from our laboratory that combined HPLC and
radioimmunoassay (RIA). ISF Ang II samples were determined
by direct RIA; and plasma, ISF bradykinin concentrations were
determined using a standard RIA kit (Phoenix Pham., Mountain
View, CA) [5]. Plasma, ISF NE and E concentrations were
Figure 7. A diagram demonstrates the hypothesized pathway of volume overload stress effect on LV remodeling and functions. The
pure stretch of volume overload induces cardiac kallikrein-kinin upregulation from cardiomyocytes and fibroblasts that result in increased ISF
bradykinin and activate kinin B2 receptor. Kallikrein and kinin cause mast cell degranulation. Mast cell degranulation causes the release of proteolytic
enzymes like tryptase and chymase, as well as other cytokines that activate MMPs. Chymase also can activate kallikreins, MMPs and degrade collagen
and non-collagen extracellular matrix components, such as fibronectin. The increase in bradykinin can further decrease extracellular matrix synthesis.
Furthermore, tissue kallikreins can activate the kinin B2 receptor in the absence of kininogen. Because the kininogen substrate is abundant in plasma
and tissues, the expression and availability of tissue kallikrein are the rate-limiting factors in kinin production.
doi:10.1371/journal.pone.0040110.g007
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Minneapolis, MN).
LV Myocardial ACE, ACE 2 and Chymase-like Activity
By using ACE-specific substrate hippuryl-his-leu, ACE activity
was defined as captopril-inhibitable hippuric acid (HA) formation
expressed as nmoles of HA formed/g/min of tissue. By using Ang
I as substrate, chymase-like activity was defined as chymostatin-
inhibitable Ang II formation expressed as nmoles of Ang II
formed/min/g of tissue [5]. ACE 2 activity was calculated based
on adding 1 nmol/L of
125I-Ang-(1–12) substrate to the reaction
mixture and determining the amount of Ang II product formation.
The enzyme activity was defined as fmoles of Ang II product
formation from
125I-Ang-(1–12) substrate per min per mg of
protein (fmol Ang II formation/min/mg protein) [35].
Western Blot Analysis
Western blots analyses for ACE 2 (rabbit antibody, 1:1,000),
MMP-2 (rabbit antibody, 1:1,000), and MMP-9 (rabbit antibody,
1:500) were performed, and bands were quantified as previously
described by our laboratory [24]. b-actin (mouse antibody 1:1,000)
was used as an internal control. All antibodies were purchased
from Abcam, Cambridge, MA. An equal amount of protein (20–
30 mg) sample was loaded and the optical density of bands was
quantified by Image J 1.44p (NIH image).
Gelatin Gel Zymography
Cell lysates (3–10 mg of protein) were loaded in a precast 10%
gelatin gel, and gel zymography was performed following the
manufacturer’s instruction (Novex, Invitrogen) as previously
described by our laboratory [24]. A proteolytic bands of 78 kDa
(MMP-9) and 62 kDa (MMP-2) were scanned and quantified with
Image J. Data are expressed as fold changes of the corresponding
control.
Real-time RT-PCR
Total RNA was extracted from LV with TRIzol reagent
(Invitrogen Corporation, Carlsbad, CA). Messenger RNA was
reversed transcribed using Transcriptor Reverse Transcriptase
(Roche Diagnostics Corporation, Indianapolis, IN). Real-time
PCR reactions were carried out using LightCycler and Light-
Cycler-FastStart DNA Master SYBR Green I kit (Roche
Diagnostics Corporation). The primers set for ACE 2, Kallikreins
1, 2, 10, BK2R and GAPDH were as follows: for ACE 2, 59 primer
was 59-GTCCAAGATCGCCCAAAATTTC and 39 primer was
59-TTTCTACGTCTTCGATCAACT (454 bp); for kallikrein 1,
59 primer was 59-AAAGCCCACACACAGATGGT and 39
primer was 59-TAGCTGGCCTATTGGTTTCG (169 bp); for
Kallikrein 2, 59 primer 59-GCTGTCATCAATGAATACCTC
and 39 primer was 59-TGGTCATGCACAGGTTGTTCA
(224 bp); for kallikrein 10, 59 primer 59-GCACCAAACCCCT-
GAATTGGG and 39 primer was 59-ACACCTGGGTTA-
TAGGGTTCA (250 bp); for BK2R, 59 primer was 59-
CCATCTCTCCACCTGCATTG and 39 primer was 59-
CGTCTGGACCTCCTTGAACT (739 bp); and for GAPDH,
59 primer was 59-ATGGTGAAGGTCGGTGTG and 39 primer
was 59-ACCAGTGGATGCAGGGAT (633 bp). Real-time PCR
conditions for the primers were optimized at 3 mM Mg
2+, 0.5 mM
primers and 40 ng cDNA in a total reaction volume of 20 ml. All
PCR products appeared as single bands of expected molecular size
by 1.5% agarose gel fractionation; they were cloned and
sequenced to identify the target cDNAs. We also verified that
each PCR product consisted of only a single species, as determined
by melting curve analysis. To determine copy number, standard
curves for each target transcript were established using purified
PCR products. They were linear and correlation coefficients were
greater than 0.99.
Quantitative Evaluation of Myocardial Mast Cells
The number of mast cells was quantitatively determined for the
entire LV wall using Giemsa-stained paraffin sections. This
method produces intense staining (purple) specific for mast cell
granules. 50–70 fields were examined using the 20x objective of
the microscope, and the number of mast cells per mm
2 was
tabulated as previously described [4,5].
Interstitial Collagen (Collagen Volume Percent) Analysis
Hearts were removed from each rat at sacrifice and immersion-
fixed in 10% buffered-formalin. Horizontal short-axis sections
through the mid-LV were embedded in paraffin, sectioned at
3 mm thickness, and stained with picric acid sirius red F3BA
(PASR). Quantitative analysis of interstitial collagen was accom-
plished by light microscopy with a video-based image-analyzer
system. Collagen volume percent was quantitatively evaluated at
high power (40x objective, 1550x video-screen magnification) with
a 540-nm green filter to provide grayscale contrast of dark collagen
fibers with light background. Using images collected by digital
camera, we determined the collagen volume percent of 30–40
randomly selected fields in each section, excluding perivascular
areas, and the mean value was calculated for each animal. All
measurements were performed in a blinded manner.
Immunohistochemistry for Tissue Kallikrein in LV
Myocardium
Immunohistochemistry were performed on the formalin fixed
paraffin-embedded LV from rats. 5 mm sections were mounted on
slides, deparaffinized in xylene and rehydrated in a graded series
of ethanol. After blocking with 1x PBS/1% Casein, overnight
incubation at 4uC with tissue kallikrein antibody (1:1000; provided
by Dr. Julie Chao; Medical University of South Carolina,
Charleston, South Carolina, United States of America), followed
by 1 hr incubation room temperature with desmin antibody
(Abcam, Cambridge, MA, 1:200) was performed. Alexa Fluor 594-
and Alexa Fluor 488-conjugated secondary antibodies (Molecular
Probes, Eugene, OR; 1:500 each) was applied to visualize the
tissue kallikrein (red) and desmin (green) in the tissue. Nuclei were
stained (blue) with DAPI (1.5 mg/ml; Vector Laboratories,
Burlingame, CA). Image acquisition (100x objective, 4000x
video-screen magnification) was performed on a Leica DM6000
epifluorescence microscope with SimplePCI software (Compix,
Inc., Cranberry Township, PA). Images were adjusted appropri-
ately to remove background fluorescence.
Cardiac Myocytes and Fibroblasts Isolation
Cardiomyocytes and fibroblasts were isolated from the 10-wk-
old Sprague-Dawley rat heart. The heart was perfused with
perfusion buffer (120 mmol/L NaCl, 15 mmol/L KCl,
0.5 mmol/L KH2PO4, 5 mmol/L NaHCO3, 10 mmol/L
HEPES, and 5 mmol/L glucose, at pH 7.0) for 8 min and
digested with perfusion buffer containing 2% collagenase II for
25 min at 37uC. The right ventricle and atria were removed
before the perfused-heart was minced. The cell suspension was
then mixed with stop buffer containing 10% fetal bovine serum
(FBS). After filtered, the flow-through was spun at 300 rpm for
3 min to pelletize the cardiomyocytes. After calcium re-introduc-
Kallikrein-Kinin System in Volume Overload
PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e40110tion, only cardiomyocytes with purity and viability (rod-shaped)
.95% or 80%, respectively, were used.
The supernatant was then resuspended in DMEM supplement-
ed with antibiotics (penicillin/streptomycin, 1%), L-glutamine
ascorbate and 10% FBS. Cells were subjected to differential
plating on uncoated cell culture plates (100 mm
2) for 45 minutes.
Non-adherent cells (mostly cardiomyocytes and smooth muscle
cells) were removed and fresh medium added. Cells were grown to
95% confluence and then detached by 0.05% trypsin/EDTA and
plated on the Bioflex culture plates with precoated collagen I.
Cultured cells were immunophenotyped by their absence of alpha
smooth muscle actin which was expressed in myofibroblast, but
presence of vimentin as fibroblast. From the staining passage one
of the fibroblasts with alpha smooth muscle actin (Figure S4, A,
green), vimentin (Figure S4, B, red) and DAPI (nuclei, blue), we
showed .95% purity (Figure S4, C, composite) of the prep and
little myofibroblast differentiation. Cardiomyocyte and fibroblast
used in the passage one were studied after deprived of serum for
24 hrs prior to cyclic stretch study.
Application of Extrinsic Mechanical Load
Cells (2x10
6) were cultured on laminin-coated Flexcell plates
(Flexcell International Corp., Hillsborough, North Carolina,
United States of America) in DMEM medium containing 10%
FBS, 2 mM glutamine, 10 U/mL penicillin, and 100 mg/mL
streptomycin. The medium without serum was changed 24 hrs
before initiation of the experiment. Cultured rat ventricular
myocytes or fibroblasts with or without aprotinin (12,000 kallikrein
inhibitor units in the medium) were subjected to cyclic strain (60
cycles/min) on the Flexcell Strain apparatus (model FX-5000;
Flexcell International, Hillsborough, North Carolina, United
States of America) at a level of distension sufficient to promote
an increment of approximately 5% in surface area at the point of
maximal distension on the culture surface. The cyclic stretch will
be performed for 24 hrs and without interruptions. Control cells
were grown in identical culture plates and incubated in the same
incubator as the stretched cultures, but were not mounted in the
Flexercell Strain Unit.
Statistical Analysis
All data were presented as mean6standard error of mean
(SEM). An unpaired Student’s t-test was used to compare 4 wk vs.
15 wk sham groups, and to compare age-matched shams vs. ACF
groups. To test the efficacy of aprotinin in ACF, a one-way
analysis of variance (ANOVA) combined with multiple compar-
isons was performed using the Holm-Sidak method in Table 4. A p
value of less than 0.05 was required for statistical significance.
Supporting Information
Figure S1 ACE 2 protein expression in the LV at 4 and
15 wk ACF and age-matched sham rats. Total protein was
extracted from LV tissue and ACE 2 protein expression was
normalized by b-actin. Representative image of western blots of
LV extracted from sham and ACF rats (upper panels).
Quantification of the bands is shown at lower panels. Values are
mean6SEM. n=6–8 in each group. **P,0.01 vs. age-matched
shams.
(TIF)
Figure S2 Expressions of kallikreins (KLKs) and BK2
receptor in stretched cells. Expressions of kallikrein (KLK) 1,
10 and BK2R mRNA in normalized to GAPDH in response to
cyclic stretch at 5% maximum strain and 1 Hz for 24 hrs with or
without aprotinin in adult cardiac myocytes and fibroblasts.
Vehicle unstretched cells were grown in identical culture plates
and incubated in the same incubator as the stretched cultures, but
were not mounted in the Flexercell Strain Unit. Values are
expressed as mean6SEM. n=4–6 in each group. *P,0.05,
**P,0.01 vs. Vehicle.
(TIF)
Figure S3 Gelatinase activity and protein expression in
stretchedcells.GelzymographyofgelatinaseactivityandMMP-
2 protein expression in 24 hrs of cyclic stretch with or without
aprotinin in adult rat cardiac myocytes and fibroblasts. There is
increased MMP-9 activity at 78 kDa in cardiomyocytes (Panel A)
andMMP-2activityat62 kDainfibroblasts(PanelB)after24 hrsof
stretch.PanelsCandD,MMP-2proteinexpressionswereincreased
inresponsetostretchinbothcells.ThegelatinaseactivityandMMP-
2 protein expressions were both reduced by aprotinin treatment.
Values are expressed as mean6SEM. n=4–6 in each group.
*P,0.05 vs. Vehicle.
(TIF)
Figure S4 Immunofluorescence revealed phenotype of
cardiac fibroblast. Cardiac fibroblasts used in our studies were
at passage one. From the staining of the fibroblasts with alpha
smooth muscle actin (A, green), vimentin (B, red) and DAPI
(nuclei, blue), we showed .95% purity (C, composite) of the prep
and little myofibroblast differentiation.
(TIF)
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